How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
By establishing coding and separate payment for certain digital mental health devices, this group from CMS and the FDA hopes to improve access to care.
AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your
The House Health and Human Services committee nearly unanimously approved a bill that would legalize synthetic psilocybin medications for certain conditions, contingent upon approval by the FDA.
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.
Pharmaceutical Technology on MSN7d
Biogen proposes acquisition of partner Sage TherapeuticsThe proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback